Herpes simplex virus infections are an enormous global health problem and there is currently no viable vaccine. For nearly three decades, immunologists’ efforts to develop a herpes vaccine have centered on exploiting a single protein found on the virus’s outer surface that is known to elicit robust production of antibodies. Breaking from this approach, Howard Hughes Medical Institute (HHMI) scientists at Albert Einstein College of Medicine have created a genetic mutant lacking that protein. The result is a powerfully effective vaccine against herpes viruses.
Infections due to the sexually transmitted bacterium Chlamydia trachomatis often remain unnoticed. The pathogen is not only a common cause of female infertility; it is also suspected of increasing the risk of abdominal cancer. A new study has now observed the breakdown of an important endogenous protective factor in the course of chlamydial infection. In other words, the pathogen can cause an increased risk of certain cancers.